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when CBT was assessed against SEGP, WMD was -12.2 (p0.024) at 4 months,
indicating that CBT (individualised therapy) demonstrated significantly better re-
duction in fatigue compared to SEGP (group therapy). CONCLUSIONS: Overall re-
sults demonstrated that CBT was significantly superior in alleviating fatigue com-
pared to no therapy, RT, and SEGP. CBT appears to be promising, acceptable and
clinically beneficial approach that could potentially benefit patients with MS fa-
tigue in future. Thus, further research is warranted to determine which aspects of
CBT are most effective and the optimal delivery of CBT for MS fatigue.
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OBJECTIVES: To report effects of BG-12 on the reduction in number of relapses
requiring intravenous steroids and multiple sclerosis (MS)-related hospitalizations
in DEFINE and CONFIRM, two Phase 3 studies of efficacy and safety of oral BG-12
(dimethyl fumarate) in patients with relapsing–remitting MS (RRMS). METHODS:
Patients aged 18–55 years with RRMS (McDonald criteria 2005) and an Expanded
Disability Status Scale score of 0–5.0 were randomized equally to oral BG-12 240 mg
twice (BID) or three times daily (TID) or placebo in DEFINE, or to oral BG-12 240 mg
BID or TID, placebo, or subcutaneous glatiramer acetate 20 mg/day (reference com-
parator) in CONFIRM. The primary endpoint at 2 years was: the proportion of pa-
tients relapsed in DEFINE, and annualized relapse rate in CONFIRM. Tertiary end-
points in both studies included number of relapses requiring intravenous steroid
therapy and MS-related hospitalizations. RESULTS: The intent-to-treat popula-
tions of the DEFINE and CONFIRM studies comprised 1,234 and 1,417 patients,
respectively. In DEFINE, BG-12 reduced the adjusted annualized rate of relapses
requiring steroids at 2 years by 52% (BID; rate ratio, 0.48 [95% confidence interval,
0.36–0.63]) and 51% (TID; 0.49 [0.37–0.64]) vs placebo (both p0.0001). Relative re-
ductions in CONFIRM were 44% (BID; 0.56 [0.42–0.76]) and 49% (TID; 0.51 [0.38–0.70])
vs placebo (p0.0002 and p0.0001). BG-12 also reduced the adjusted annualized
rate of MS-related hospitalizations at 2 years in DEFINE by 35% (BID; 0.65 [0.41–1.04])
and 45% (TID; 0.55 [0.34–0.88]) vs placebo (p0.0708 and p0.0125); relative reduc-
tions in CONFIRM were 32% (BID; 0.68 [0.42–1.09]) and 50% (TID; 0.50 [0.30–0.85]) vs
placebo (p0.1092 and p0.0098). CONCLUSIONS: These findings further support
the positive efficacy results for the primary and secondary clinical endpoints in
DEFINE and CONFIRM, and also suggest potential health economic benefits of
BG-12 treatment for relapsing MS.
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OBJECTIVES: To demonstrate the clinical effectiveness of capsaicin 8% patch
monotherapy in the treatment of post-herpetic neuralgia (PHN) using an integrated
analysis of individual patient data from Phase III studies. METHODS: Data from
four double-blind randomized controlled trials of patches containing either capsa-
icin 8% w/w (QTZ) or 0.04% capsaicin w/w (CTRL). Study subjects did not use con-
comitant neuropathic pain medication (either opioid, anticonvulsant, or antide-
pressant) during study period and received a 60-minute patch application. The
primary endpoint was percentage change in numeric pain rating scale (NPRS) “av-
erage pain for the past 24 hours” score between Baseline and Weeks 2-8 (week 12 as
secondary endpoint) following treatment. The proportion of subjects achieving a
30% decrease in their “average pain” NPRS scores from Baseline to Weeks 2–8
(“Responders”) was also analysed. The primary endpoint was analysed with a gen-
eral linear model with subject baseline characteristics and study allocation entered
as fixed effects and trial subgroup entered as a random effect. Statistical signifi-
cance for all tests was p0.05. RESULTS: A total of 533 subjects received capsaicin
monotherapy; 55% received QTZ. QTZ and CTRL subgroups had near-identical
baseline characteristics for gender (48% male), age (70.2 years); PHN duration (3.7
years), baseline “average” pain (5.5), and treatment area size (321cm2). The ad-
justed estimated marginal mean percentage change in pain from Baseline to Week
8 was -36.9% (95% CI: -40.9 to -32.0) for QTZ and -27.3 (-32.0 to -22.7) for CTRL
(p0.001). Baseline to Week 12 percentage change similarly favoured QTZ
(p0.001). At week 8, 52% of QTZ subjects were responders compared with 40% of
controls (p0.007). The adjusted odd-ratio for treatment response was 1.66 (95% CI:
1.15 to 2.40) in favour of QTZ. CONCLUSIONS: Capsaicin 8% patch monotherapy is
a clinically effective treatment option for post-herpetic neuralgia when compared
to low-dose active comparator.
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OBJECTIVES: To compare, in the absence of head-to-head trials, the clinical benefit
of gabapentin enacarbil, levodopa, pramipexole, ropinirole, and rotigotine in the
treatment of moderate-to-severe restless legs syndrome (RLS).METHODS:A mixed
treatment comparison (MTC) was performed using the Bayesian approach in the
software WinBUGS. A systematic literature review was first conducted to identify
RLS trials published over the past ten years through search on MEDLINE, EMBASE,
Cochrane CENTRAL and manufacturers’ websites. Twenty-eight clinical trials were
retained after two screenings. To minimize heterogeneity on dosing and trial du-
ration, a smaller set of fifteen trials were included in the primary analysis, com-
prising 4,413 patients. A sensitivity analysis was then performed on the full set of
twenty-eight trials to validate the results of the primary analysis. RESULTS: The
indirect comparison was established among four active treatments (gabapentin
enacarbil, pramipexole, ropinirole, rotigotine) and placebo, due to the lack of latest
clinical evidence on levodopa. Analysis on the primary endpoints indicates that
rotigotine is most likely to lead to the greatest reduction in IRLS score from baseline
(probability of 64.7% at the end of maintenance, and of 70.6% at week 12). Rotigo-
tine’s comparative therapeutic benefit is also observed in IRLS responders rate and
in five out of six items of the RLS-6 scale. CONCLUSIONS: Based on the results of
this MTC, rotigotine is most likely the most efficacious treatment option to alleviate
RLS symptoms. Head-to-head clinical trials should be conducted to confirm the
findings of this MTC.
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OBJECTIVES: The advent of new, costly disease-modifying-therapies (DMT) for
multiple sclerosis (MS) requires consideration of all evidence on comparative ef-
fectiveness with existing therapies to inform both health policy and clinical care.
This study compares the relative effectiveness of DMTs within a mixed treatment
comparison (MTC) framework, and explores the contribution of real-world evi-
dence from observational studies to the evidence-base. METHODS: Sixteen ran-
domised controlled trials (RCTs) and four observational studies incorporating nine
DMTs were identified according to specified inclusion criteria following a system-
atic review of the literature. A Bayesian MTC model was fitted in WinBUGS, for the
outcome Annualised Relapse Rate (ARR). Alternative methods of combining data
from different trial designs were used. The model was extended to a meta-regres-
sion to include baseline covariates. RESULTS: Natalizumab and Fingolimod, two
recently approved DMTs, were significantly more effective than other DMTs for the
ARR outcome versus placebo, while the least effective option was Interferon be-
ta-1a 6MIU. Minimal differences were observed among the other DMTs. Baseline
covariates had no significant impact on the results. Observational data was avail-
able only for the older DMTs. An MTC of these trials supported the ranking in
effectiveness obtained from the RCT MTC, although individual estimates of effec-
tiveness were different to RCT estimates and uncertainty was substantial. As an
alternative to naïve pooling of both RCT and observational data, utilising the ob-
servational data as prior information allowed for adjustment of bias due to trial
design. CONCLUSIONS: Relative clinical effectiveness of DMTs is an important
component in the assessment of cost-effectiveness of these agents. RCTs provide
the foundation for evaluating comparative effectiveness of DMTs. However, obser-
vational studies can contribute complementary evidence on important compara-
tive effectiveness questions.
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OBJECTIVES: This study aimed to analyse the pattern of prescription and use of
antiepileptic drugs (AEDs), being its main focuses the characterization of off-label
use and its costs. METHODS: Cross sectional survey, carried out from Sept. 2009 to
Feb. 2010 in 20 pharmacies of Lisbon Region. Inclusion criteria: pharmacy users with
a prescription including at least 1 AED (all medicines listed under the Anatomical
Therapeutic Chemical code N03-Antiepileptics, having epilepsy in the SPC as main
indication). Information was collected by interview, conducted by trained phar-
macy students based on self-reported data. Prescription expenditures were ob-
tained by crossing the official price of each medicine single unit, at the time of the
study, with data on posology reported by each patient. Aggregate annual expendi-
tures were calculated based on that information. RESULTS: Data from 543 patients
was analyzed (61.3% females), age range 2-91 years (mean: 50.9). The main con-
sumed AEDs were valproic acid (18.0%), pregabalin (16.2%), topiramate (15.7%) and
carbamazepine (14.7%). The first prescriber was in 36.1% of the cases a neurologist
and in 31.9% a psychiatrist. Epilepsy was the indication in 29.5% of the patients.
Off-label use was found in 33.1% of the sample. Among the off-label sample, topi-
ramate (28.2%), clonazepam (17.2%), valproic acid (16.7%) and gabapentine (10.9%)
were the anticonvulsants most widely used off-label. Clonazepam (85.7%) and topi-
ramate (59.0%) had most of their uses in off-label indications. Psychiatrists (59.2%)
were the prescribers in the majority of the off-label cases. The main off-label indi-
cations were depression (31.4%) and mood stabilization (19.4%). Total costs with
AEDs were 210,851.57€ in which 48,424.04€ (23.0%) represents an off-label cost.
CONCLUSIONS: Approximately 1/3 of the sample used AEDs in off-label indica-
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tions. Extrapolating to national data, it is estimated that more than €14 billion were
paid for AEDs in off-label use (more than €13 billion paid by the NHS).
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OBJECTIVES: Multiple sclerosis (MS) is a chronic inflammatory disease with 12,000
new diagnoses per year in the United States. Higher latitude is associated with
higher MS prevalence rates, and the female-to-male ratio in MS incidence has been
estimated at 2:3 in 2000. This study aims to estimate the prevalence and incidence
rate of MS in the United States. METHODS: Patients with an MS diagnosis (Inter-
national Classification of Diseases Ninth Revision Clinical Modification [ICD-9-CM]
code: 340.XX) between January 2006 and December 2010 were identified from a
large U.S. claims database. Prevalence rates from 2006 to 2010 were calculated by
dividing the number of MS patients by the total number of health plan enrollees in
each year. The 2010 incidence rate was calculated by dividing the number of pa-
tients with a new MS diagnosis in 2010 by the total number of enrollees in 2010.
RESULTS: The prevalence rate remained stable at 0.16% from 2006 to 2008, and
then increased in 2009 (0.17%) and again in 2010 (0.19%). In 2010, MS prevalence in
women (0.26%) was more than twice the rate than that of the male population
(0.09%). To examine regional differences, prevalence rate was also calculated for
each U.S. state. Regional prevalence rates ranged from 0.11% (Arkansas) to 0.29%
(Rhode Island). The estimated incidence rate for 2010 was 0.03% for the overall
population, 0.05% for female, and 0.02% for male patients. Incident cases had an
average age of 49 years, and were more likely to suffer from comorbid conditions,
such as disturbance of skin sensation, fatigue, and hypertension. Incidence rates
by state ranged from 0.01% (Maine) to 0.08% (Michigan). CONCLUSIONS: This study
confirms that MS prevalence and incidence rates are higher in female patients, and
in regions farther away from the equator.
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OBJECTIVES: One important aspect for patients suffering from multiple sclerosis
(MS) is the frequency and severity of relapses that lead to a significant increase in
symptoms and an aggravation of health related quality of life. In this study, data of
about 3,000 MS patients have been analysed over a five year period in order to
identify the number of relapses and the events that may follow a relapse.
METHODS: Information was taken from 2006 to 2010 German claims data. To iden-
tify a relapse, several indicators such as hospitalisations, specific relapse medica-
tion and outpatient consultations have been investigated. RESULTS: The results
show that the identification of relapses can be achieved by including inpatient,
outpatient and relapse medication data. Relapses were found for 47% of all MS
patients. Among those receiving MS medication, 67% suffered from relapses while
only 32% of the patients without medication were affected. This may indicate that
the proportion of patients having a higher risk of relapses is usually under MS-
treatment. Most patients with relapses (64%) did not show more than three re-
lapses within five years. The events following a relapse were classified by the
number of hospitalisations (14% within one month after the relapse), transitions
from basic to escalating MS medication (3% within one quarter after the relapse) or
changes of disease modifying drug (3% within one quarter after the relapse).
Changes of basic MS medication are not necessarily related to relapses, while
changes from basic to escalating MS medication are often observed after such an
event. CONCLUSIONS: Patients with high frequencies of relapses are treated with
disease modifying drugs more often than other patients. Most of the MS patients do
not suffer from relapses within the observation period of five years, with a small
group of patients suffering from numerous relapses.
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OBJECTIVES: To explore the impact of severity and rate of decline of cognitive
impairment on mortality within Alzheimer’s disease (AD) patients. METHODS:
Data on AD patients were from CERAD (Consortium to Establish a Registry for
Alzheimer’s Disease), a US multicenter, longitudinal study. Patient demographics,
cardiovascular and other co-morbidities, activities of daily living (ADL), cognitive
impairment measured by the Mini-Mental State Examination (MMSE) and Clinical
Dementia Rating (CDR), and survival status were obtained at study entry (baseline),
and at annual follow-up visits. Study survival time was modelled as a function of
patient baseline demographics, cognitive impairment at entry and its decline over
time using parametric survival models and semi-parametric Cox proportional haz-
ard model (PH), with decline of cognitive impairment as a time-dependent
covariate. RESULTS: 1010 patients with non-missing survival data were included in
the analysis. At baseline, men, age and cognitive impairment significantly in-
creased the mortality risk (p0.001 for all). Additionally, patients progressing to a
more severe stage of cognition over time had significantly higher mortality risk
(p0.001), with a hazard ratio for CDR change over time versus baseline as a time
dependent covariate of 1.35 [95% CI: 1.21-1.51]. CDR and MMSE scores were highly
correlated; results based on models using either CDR or MMSE were mostly consis-
tent. Results were confirmed by sensitivity analyses with varying modelling
assumptions. CONCLUSIONS: Severity and rate of decline of cognitive impairment
are both strong predictors of survival in AD, additional to the usual demographic
and clinical patient characteristics. These findings suggest that treatments delay-
ing the progression of AD patients to more severe stages of cognitive impairment
might positively impact overall survival.
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OBJECTIVES: Cystic fibrosis (CF), the most common lethal genetic disease in Cau-
casians, causes a high burden of disease. Median age at death is in the late 20s with
the most common mode of death being respiratory failure. Treatment with iva-
caftor, a CF transmembrane conductance regulator (CFTR) protein potentiator, was
generally safe and improved risk-factors for mortality in CF, including pulmonary
function, weight and pulmonary exacerbations. Since controlled clinical trials can-
not directly demonstrate survival benefits, we estimated the potential for survival
benefit from drug therapies based on similar, observed short-term changes to risk
factors known to impact survival in CF. METHODS: Survival information for CF
patients in Germany, France, the UK, and Ireland was obtained from national reg-
istries and individually fitted to a Weibull function. From these survival curves the
hazard function for an average CF patient was calculated as a function of age. The
impact to the hazard function from improvements in risk factors (FEV1, weight-
for-age z-score, pancreatic sufficiency, diabetes, Staphylococcus aureus, Burkholderia
cepacia, and annual number of pulmonary exacerbations) was estimated using pre-
viously published Cox proportional hazards model for CF mortality. RESULTS: For
each country, a survival function was developed taking into account current aver-
age mortality rates and estimated long-term changes to risk factors. Sensitivity
analysis suggest that it is possible for drugs that improve clinical outcomes in CF,
including pulmonary function, weight and pulmonary exacerbations, to add a de-
cade to the median life expectancy CF patients. CONCLUSIONS:Modeling suggests
that therapies that improve clinical risk factors for mortality in CF, including pul-
monary function, weight and pulmonary exacerbations, may extend the lives of CF
patients.
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OBJECTIVES: To estimate the economic impact of introducing the test for diagnos-
ing the five cardiopathies associated to SCD related to the currently best known
genes in Spain: 1.Hypertrophic Cardiomyopathy (HCM); 2.Arrhythmogenic Right
Ventricular Cardiomyopathy (ARVC); 3.Long-QT Syndrome (LQTS); 4.Brugada Syn-
drome (BrS), and 5.Catecholaminergic Polymorphic Ventricular Tachycardia
(CPVT). METHODS: A 3-year budget impact analysis was carried out based on in-
ternational sources of epidemiological and health care resource utilization data;
local input costs and market share, and expert opinion. Two scenarios were com-
pared: current clinical practice (with no genetic testing) vs. alternative practice
(with genetic testing). The perspective adopted was that of the Spanish National
Healthcare System (NHS). All costs referred to €, 2012. RESULTS: The target popu-
lation at risk of SCD was estimated on 25,220 patients for year 1; 26,352 for year 2,
and 26,340 for year 3. Genetic testing would be conducted in 350, 550 and 700
patients in 2012, 2013 and 2014, respectively. The budget impact of introducing the
genetic testing would imply an additional cost of € 309,187, € 532,311, and € 724,404,
respectively. Genetic testing compared to current practice would imply cost sav-
ings of € 10,152 and of € 41,062, in the first year; of € 30,327 and € 84,026, in the
second, and of € 57,269 and € 126,660 in the third year derived from two reasons:
preventing new events in patients at risk and from averting follow-up in patients at
no risk, respectively. CONCLUSIONS: Potential cost savings derived from prevent-
ing new events and unnecessary follow-up may overcome the costs of introducing
the genetic testing for HCM, ARVC, LQTS, BrS and CPVT in the Spanish NHS.
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OBJECTIVES: Cirrhosis and its complications, such as hepatic encephalopathy (HE)
are the sixth cause of general mortality in Mexico. The objective is to update costs,
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